X hits on this document

113 views

0 shares

0 downloads

0 comments

27 / 30

Tykerb Summary

  • Tykerb is an orally available, reversible, small-molecule inhibitor of EGFR/ErbB2

  • Safety and tolerability demonstrated in Phase I studies, with healthy volunteers as well as cancer patients

  • Clinical responses were observed at a variety of doses in heavily pre-treated subjects with metastatic disease

  • Approved by the FDA in March 2007 for use in metastatic breast cancer in combination with Xeloda for pateints that have progressed on prior therapy

  • Additional studies under way in a number of tumor types, either as monotherapy or in combination with other therapies

Document info
Document views113
Page views113
Page last viewedTue Jan 17 09:42:06 UTC 2017
Pages30
Paragraphs319
Words1235

Comments